News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sunovion Pharmaceuticals Inc. Presents Data Showing 12 Months of Latuda® (lurasidone HCl) Treatment Resulted in Higher Remission Rates in Adult Patients With Schizophrenia Compared to Seroquel XR® (quetiapine XR)


5/21/2013 10:51:38 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. today announced results from a post-hoc study analysis showing that adult patients with schizophrenia who were treated with Latuda® (lurasidone HCl) were more likely to achieve sustained remission over 12 months of treatment compared to patients taking Seroquel XR® (quetiapine XR). The analysis utilized remission criteria that were established by the Research in Schizophrenia Working Group in 2005.1 In addition, over the 12-month study period, patients treated with quetiapine XR discontinued at a greater rate than patients treated with LATUDA.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES